Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Anheart, Antengene, Aravax, Ascletis, Astellas, Beigene, Bharat, Biogen, Carsgen, Eisai, Harbour, HLB, Hutchmed, I-Mab, Innocare, Innovent, JW, Merck, Ocugen, Redcloud, Regenerx, Seagen, Sorrento, Statera, Valneva.